The conference room settled into a hushed anticipation as Xavier Wellington, the President of Osborn Pharmaceutical and Biotech Group, adjusted his glasses and rose to present his report. With the quiet precision of a seasoned surgeon, Xavier exuded confidence—his tailored navy suit was immaculate, salt-and-pepper hair slicked back neatly, and sharp green eyes that seemed to absorb every detail in the room.

Arthur leaned back in his chair, gesturing for Xavier to begin. “Let’s hear how our medical division is performing, Xavier.”

With a tap on the table, various data points illuminated the holographic screens around them. “I’ll kick things off with our flagship product: the AMHP-9 Emerald Rebirth Pod.” The screens displayed stunning 3D schematics of the sleek oval-shaped pod that had transformed skin reconstruction globally.

“Current sales stand at an impressive 18.7 million units worldwide,” Elias reported calmly. “At our standard price of 42 million Unicreds per unit, that’s a staggering 785.4 trillion Unicreds in revenue—with a robust profit margin of 74% after production and distribution costs.”

Margaret paused mid-note. “What’s fueling this sustained demand?”

Xavier zoomed in on different hospital installations across the globe as he answered confidently. “There are three key factors: First, we face zero competition; no other technology can rival our results. Second, we’ve expanded our approved applications from burn treatment to cosmetic reconstruction. And third,” he pointed to a military field hospital image on screen, “our recent contracts with the Department of Defense for battlefield deployment.”

Arthur leaned forward slightly. “And what about production capacity?”

“We’ve ramped up operations to twelve manufacturing facilities across six countries,” Elias replied smoothly. “Our current output is 3.2 million units per month—with plans to double that by next fiscal year.” He pulled up new data highlighting their success in the Aurelian Federation: they now hold an astonishing 87% market share in skin reconstruction.

Julian let out a soft whistle as a smile crept onto his face. “That’s complete domination!”

Xavier allowed himself a small nod of satisfaction. “Indeed! Our nearest competitor, Voss-Keller Pharmaceuticals, has seen their market share plummet from 38% to just 6% over the past eight months.”

Arthur took a slow sip from his drink before asking thoughtfully, “I trust they haven’t taken this lying down?”

A rare smirk crossed Xavier’s usually impassive face. “They tried developing a competing unit priced at 30 million Unicreds—but it didn’t go well for them. Eleven class-action lawsuits later, they’ve withdrawn it entirely.”

Laughter rippled through the room before Xavier moved on smoothly to his next topic: “Now let’s talk about our VitaCore Emerald Liquid.”

**The Future of Medicine and Finance: A Glimpse into Innovation**

As the display flickered to life, showcasing a mesmerizing green solution across various medical settings, the atmosphere in the room buzzed with anticipation.

“At 2 million Unicreds per liter, we’ve already shipped 62 million liters globally—this product is even more sought after than the AMHP-9 Emerald Rebirth Pod!” Elias exclaimed, his enthusiasm palpable. “Military contracts alone account for nearly 40% of our sales, with the Lantier Union snapping up an impressive 8 million liters.”

Nathaniel raised an eyebrow, curiosity piqued. “Any production challenges with that kind of volume?”

“We’re on track,” Xavier replied confidently. “We’ve broken ground on a dedicated facility in the Titan Reach zone within the Lantier Union. Once it’s completed next quarter, it will triple our current output.” He scrolled through data on his tablet. “Efficacy remains at an astonishing 99.997%, and those minor allergic reactions we initially encountered? Completely eliminated in our latest formulation!”

Ashley leaned forward, her designer glasses reflecting the screen’s glow like a beacon of insight. “What about consumer-grade products? I’m particularly interested in the NanoGel EM1 Quick Patch.”

Xavier smoothly transitioned to showcase the NanoGel EM1 QuickPatch display. “We’ve sold 5 billion units at 700 Unicreds each! The profit margin is surprisingly higher than our premium products—82%, thanks to our massive scale of distribution.”

Richard frowned at his tablet, skepticism creeping in. “That seems counterintuitive.”

“Not really,” Elias explained patiently. “We’re shipping these by cargo freighter loads to hospitals, schools, and workplaces all over—not just here but globally! Our manufacturing process is so streamlined now that our per-unit cost is barely 126 Unicreds.”

Arthur set down his glass with a deliberate clink and asked, “And what about competition?”

Xavier’s expression turned serious as he replied, “We’ve logged 112 attempted reverse-engineering efforts, along with 29 sabotage attempts and 17 cases of corporate espionage just this past quarter.”

Margaret narrowed her eyes thoughtfully. “That’s quite brazen.”

“Desperation,” Xavier corrected firmly. “When faced with technology that’s five years ahead of anything else on the market, some firms will resort to anything.” He tapped his tablet to bring up security footage from a lab break-in. “But we’ve handled each incident decisively; our counterintelligence protocols have proven exceptionally effective.”

“Good!” Arthur nodded while drumming his fingers on the table.

Xavier smiled slightly before continuing, “Notably, both GenTech and Voss-Keller have quietly shut down their competing research programs in these areas.”

A satisfied silence enveloped the room as Arthur studied reports intently before speaking again.

**”Xavier,” he said finally, “you’ve built something remarkable here. What’s your next move?”**

Xavier didn’t miss a beat. “Three initiatives,” he replied confidently. “First, we’re expanding AMHP-9 applications to include organ scar tissue reduction. Second, we’re developing a battlefield version of the VitaCore solution that doesn’t require refrigeration; combined with the AMHP-9 Emerald Rebirth Pod, the effects will be groundbreaking. And third,” he tapped his tablet, bringing up an intricate molecular diagram, “we’re in the final testing phases for what we’re calling the ‘Phoenix Protocol’—a complete cellular regeneration treatment. This technology you provided us is nearing the research stage.”

Julian’s eyebrows shot up in disbelief. “You’re joking.”

He wasn’t alone; shock rippled through the room as everyone turned wide-eyed toward Arthur and Xavier.

“We never joke about medical breakthroughs,” Elias interjected dryly. “Initial trials show promise in reversing age-related cellular degradation. The implications are… significant.”

Arthur’s gaze sharpened with curiosity. “Human trials?”

“Nine months out,” Elias confirmed. “The ethical considerations alone will require careful navigation.”

Margaret leaned forward, her eyes sparkling with excitement. “And what about profit potential?”

Xavier allowed himself a small smile. “If even half our projections hold? We could add another zero to our annual revenue figures.”

Source: Webnovel.com, updated by NovelKeep